Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK556374PMID: 32352702
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 162401-32-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of roflumilast in nursing mothers. The drug and its metabolite are more than 97% bound to plasma proteins, so amounts in milk are likely to be very low. However, the manufacturer and some experts recommend that the oral drug should not be used by women who are nursing.[1]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
References
- 1.
- Yaghi M, McMullan P, Truong TM, et al. Safety of dermatologic medications in pregnancy and lactation: An Update - Part II: Lactation. J Am Acad Dermatol 2024. [PubMed: 38280680]
Substance Identification
Substance Name
Roflumilast
CAS Registry Number
162401-32-3
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubChem SubstanceRelated PubChem Substances
- PubMedLinks to PubMed
- Review The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.[Pulm Pharmacol Ther. 2010]Review The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H. Pulm Pharmacol Ther. 2010 Aug; 23(4):235-56. Epub 2010 Apr 7.
- In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.[J Pharmacol Exp Ther. 2001]In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. J Pharmacol Exp Ther. 2001 Apr; 297(1):280-90.
- Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.[J Pharmacol Exp Ther. 2009]Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.Izikki M, Raffestin B, Klar J, Hatzelmann A, Marx D, Tenor H, Zadigue P, Adnot S, Eddahibi S. J Pharmacol Exp Ther. 2009 Jul; 330(1):54-62. Epub 2009 Apr 22.
- Review Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869.[Drugs R D. 2004]Review Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869.. Drugs R D. 2004; 5(3):176-81.
- Review [Pharmacological profile of roflumilast].[Arch Bronconeumol. 2010]Review [Pharmacological profile of roflumilast].Cortijo Gimeno J, Morcillo Sánchez E. Arch Bronconeumol. 2010 Dec; 46 Suppl 10:19-24.
- Roflumilast - Drugs and Lactation Database (LactMed®)Roflumilast - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...